tiprankstipranks
NeuroBo Pharmaceuticals: FDA clears IND for Phase 2a trial of DA-1241
The Fly

NeuroBo Pharmaceuticals: FDA clears IND for Phase 2a trial of DA-1241

NeuroBo Pharmaceuticals announced that the U.S. FDA has cleared its Investigational New Drug application for DA-1241, a novel G-Protein-Coupled Receptor 119 agonist. The company plans to initiate a two-part, Phase 2a clinical trial of DA-1241, for the treatment of nonalcoholic steatohepatitis, in the third quarter of 2023.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on NRBO:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles